Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-509 in Amyotrophic Lateral Sclerosis
NCT00748501Phase 2Completed
- Sponsor
- Sangamo Therapeutics
- Start
- Sep 2008
- Primary completion
- Jun 2010
- Modality
- Gene Silencing, Plasmid DNA, Zinc Finger Nucleases
- Countries
- 1
01
Overview
A Phase 2 trial of SB-509 in amyotrophic lateral sclerosis (ALS), sponsored by Sangamo Therapeutics. Started Sep 2008; status: completed.
02
Drugs
SB-509
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT00748501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00748501.